Clinical Decision Rule Can Classify Risk of Chronic Back Pain

Clinical Decision Rule Can Classify Risk of Chronic Back Pain

BY ADMIN /   THURSDAY, 28 JANUARY 2016 /

A clinical decision rule with eight items can classify patients with acute low back pain by their risk for chronic pain, according to a study published in the July 1 issue of The Spine Journal.

A clinical decision rule (CDR) with eight items can classify patients with acute low back pain (LBP) by their risk for chronic pain, according to a study published in the July 1 issue of The Spine Journal.

Wolf E. Mehling, M.D., from the University of California, San Francisco, and colleagues conducted a prospective cohort study of risk factors for the progression to chronic pain. Six hundred five patients with acute LBP (≥30 days’ duration) were included, and they were surveyed at baseline, six months, and two years.

The researchers found that 13 and 19 percent of the patients had chronic pain at six months and two years, respectively. An eight-item CDR was deemed most parsimonious for classifying patients into three risk levels. For the six-month CDR, the bootstrapped area under the curve was 0.76. There was an odds ratio of 11.1 for developing chronic pain for each 10-point score increase. Likelihood ratios were 0.26 and 4.4, respectively, using a less than 5 percent probability of chronic pain as the cutoff for low risk and greater than 40 percent probability for high risk.

“A CDR was developed that may help primary care clinicians classify patients with strictly defined acute LBP into low-, moderate-, and high-risk groups for developing chronic pain and performed acceptably in 1,000 bootstrapped replications,” the authors write. “Validation in a separate sample is needed.”

Integrity Life Sciences delivers a multitude of orthotic treatment options to address one of the most costly systemic ailments in the world, chronic low back and neck pain. Our advanced solution begins with the Integrity Spinal Care System (ISCS) ™ and its proprietary iELCiPS Technology™. The ISCS non-surgical spinal decompression modality systems are engineered to provide pain relief for compressive and degenerative conditions of the spine. Specifically, conditions that may be treated include: neck pain and back pain associated with herniated discs, protruding discs, degenerative disc disease, posterior facet syndrome, and sciatica. It achieves these effects through decompression of intervertebral discs, that is, unloading due to distraction and positioning.

As a compliment to the ISCS, Integrity offers the very effective Integrity Gel Support Brace™. Our advanced lumbar support brace is a fitting compliment to non-surgical spinal decompression therapy and was designed as an adjunct therapy for those suffering from back pain due to disc related conditions. The Integrity Gel Support Brace may be used with or without Integrity’s non-surgical spinal decompression systems and is an excellent treatment option for the patient to use at home.

In addition, Integrity Life Sciences has been exclusively granted the use of all of the technology, products, US Patent and Trademark Office’s assignments, logos and other forms of intellectual property that were created by Axiom Worldwide, INC under the leadership of Jim Gibson from Tampa, Florida. The agreement specifically includes the flagship product DRX 9000™, its family of products, and all of its derivatives such as the DRX9000C. Integrity offers support for these products, which includes: sales, maintenance services, and repairs. Only Integrity Life Sciences is Registered with the US FDA as a Factory Authorized – Contract Manufacturer – for Axiom Worldwide and the DRX9000 True Non-Surgical Spinal Decompression Systems™

James Gibson, President of Integrity Life Sciences and Axiom Worldwide states “Our partners, in over 50 countries and territories, have the unique opportunity to present a cutting edge medical device, utilizing a clinically validated protocol that restores a patient’s quality of life non-surgically and without pharmaceutical or invasive intervention“. With a body of published clinical research from around the world will support and strengthen your sales presentation; members of our medical advisory board herald from prestigious institutions such as Johns-Hopkins and The Mayo Clinic just to name a few. In addition, partners will have confidence in a quality product that adheres to the stringent standards mandated by FDA, CE, and ISO. Sales, marketing, and technical training is offered in prestigious locations in Europe, Asia, the Middle East and throughout the United States.

Learn more @: www.IntegrityLifeSciences.com or www.AxiomWorldwide.com

Integrity Life Sciences, LLC and Axiom Worldwide, INC are privately held companies with global interests and shareholders with international partners located across the globe with a mission of “Restoring Integrity to the Spine™” and delivering "True Non-Surgical Spinal Decompression"

For additional information please visit: www.IntegrityLifeSciences.com.

Elements as Published in: Spine Journal